JP2001033454A - Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece - Google Patents

Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece

Info

Publication number
JP2001033454A
JP2001033454A JP11234484A JP23448499A JP2001033454A JP 2001033454 A JP2001033454 A JP 2001033454A JP 11234484 A JP11234484 A JP 11234484A JP 23448499 A JP23448499 A JP 23448499A JP 2001033454 A JP2001033454 A JP 2001033454A
Authority
JP
Japan
Prior art keywords
substance
detected
internal control
concentration
signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11234484A
Other languages
Japanese (ja)
Inventor
Hisahide Hiura
久英 日裏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sysmex International Reagents Co Ltd
Original Assignee
International Reagents Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Reagents Corp filed Critical International Reagents Corp
Priority to JP11234484A priority Critical patent/JP2001033454A/en
Publication of JP2001033454A publication Critical patent/JP2001033454A/en
Pending legal-status Critical Current

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PROBLEM TO BE SOLVED: To accurately determine with high specificity by utilizing a combination of a ligand pair substantially not effected by an influence of a substance coexisting in a sample to be detected to an internal control installed in an apparatus. SOLUTION: A sample to be detected is reacted with standard particles, and moved by a capillary flow in a matrix. A reaction composite is captured by an antigen held in a detecting region, and its signal is detected. Meanwhile, an internal control holds a gold colloid or fluorescence labeled latex particles in which an avidin is adsorbed on a test piece as a substance of reaction pair not substantially affected by an influence of the substance coexisted in the sample. Then, a biotin is previously held in the internal control area to capture moved avidin particles by an avidin-biotin bonding reaction. This signal is detected to obtain an internal control signal. A ratio of both the signals is obtained, compared with a working curve line data obtained from the sample of known concentration and the substance to be detected is determined.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は臨床検査に用いられ
る免疫測定法及び装置に関する。
The present invention relates to an immunoassay method and apparatus used for clinical examination.

【0002】[0002]

【従来の技術】毛管流を利用するリガンド測定法及び装
置は免疫クロマト測定法として広く臨床検査に用いられ
ている。この測定法は目視的な検出により被検物質を定
性的もしくは半定量的に検出するのが一般的である。一
方、このタイプの免疫測定法により被検物質を定量的に
測定する試みも示されている。例えば、特開平8−24
0591によれば、試験片の一区域に被検物質と同種も
しくは類似の物質を保持しておきこの区域を内部コント
ロールとして免疫反応により標識物と反応した信号を検
出する。そして被検物質と免疫結合対を形成する標識物
の複合体を検出する区域で生じる信号と上記の内部コン
トロール域で生じる信号の比率を求めて被検物質を定量
する方法が開示されている。この方法では、被検物質に
よる信号と内部コントロール域の信号が逆比例関係にな
ることを利用して被検物質を定量することを特徴として
いる。更に、米国特許US5753517によれば、被
検物質とは異なる免疫反応を内部コントロールとする方
法が開示されている。この方法は内部コントロール域の
信号は被検物質の濃度に依存することなく一定で、内部
コントロール域の信号と被検物質の信号の比率を求める
ことにより、被検物質を定量している。これらの何れの
方法も内部コントロールの信号を生じさせる工程におい
て、抗原−抗体反応による免疫反応を利用している。米
国特許US5753517の方法によれば、抗体を吸着
させた内部コントロール粒子を準備しておき、内部コン
トロール域において粒子に吸着させておいた抗体と免疫
反応する結合対を保持させているために、抗原−抗体反
応により内部コントロールの信号が生じるように設計さ
れている。このように抗原−抗体反応を利用した内部コ
ントロールでは、通常用いる生体試料(例えば、血液、
血清等)中に、種々の動物に対する抗体や、リウマチ因
子が含まれる検体が数多く存在するため、目的とする特
異的な免疫反応以外の非特異免疫反応が起こり、正確な
測定ができないといった欠点があった。
2. Description of the Related Art Ligand measuring methods and devices utilizing capillary flow are widely used in clinical tests as immunochromatographic measuring methods. In this measurement method, a test substance is generally qualitatively or semi-quantitatively detected by visual detection. On the other hand, attempts have been made to quantitatively measure a test substance by this type of immunoassay. For example, JP-A-8-24
According to 0591, a substance which is the same or similar to the test substance is held in one area of the test piece, and a signal which has reacted with the label by immunological reaction is detected using this area as an internal control. A method is disclosed in which a ratio of a signal generated in an area for detecting a complex of a label and an analyte to form an immune binding pair with a signal generated in the internal control area is determined to quantify the test substance. This method is characterized in that the amount of the test substance is determined by utilizing the fact that the signal from the test substance and the signal in the internal control area have an inverse proportional relationship. Further, US Pat. No. 5,753,517 discloses a method in which an immune reaction different from a test substance is used as an internal control. In this method, the signal in the internal control area is constant without depending on the concentration of the test substance, and the test substance is quantified by obtaining the ratio between the signal in the internal control area and the signal of the test substance. All of these methods utilize an immune reaction by an antigen-antibody reaction in the step of generating an internal control signal. According to the method of US Pat. No. 5,753,517, internal control particles to which an antibody is adsorbed are prepared, and a binding pair that immunoreacts with the antibody adsorbed to the particles is retained in the internal control region. -Designed such that the antibody reaction generates an internal control signal. As described above, in the internal control using the antigen-antibody reaction, a commonly used biological sample (for example, blood,
Serum, etc.), there are many samples containing antibodies against various animals and rheumatoid factors, and non-specific immune reactions other than the specific immunological reaction of interest occur, making accurate measurement impossible. there were.

【0003】[0003]

【解決しようとする課題】毛管流を利用するリガンド測
定法及び装置において、被検物質を定量する方法及び装
置を提供する。
SUMMARY OF THE INVENTION In a method and an apparatus for measuring a ligand utilizing capillary flow, a method and an apparatus for quantifying a test substance are provided.

【0004】[0004]

【解決する手段】本発明者らは鋭意研究を重ねた結果、
毛管流を利用するリガンド測定法及び装置に設置される
内部コントロールに被検試料中に共存する物質の影響を
実質的に受けないリガンド対の組合わせを利用すること
により、正確で特異性の高い定量法を提供できることを
見出し、本発明を完成させるに至った。
[Means for Solving] As a result of intensive studies, the present inventors have found that
Accurate and highly specific by utilizing a combination of ligand pairs that are substantially unaffected by substances coexisting in the test sample for the ligand measurement method using capillary flow and the internal control installed in the device They have found that a quantitative method can be provided, and have completed the present invention.

【0005】例えば、被検物質(抗原)を免疫クロマト
測定により定量する場合、金コロイドや着色もしくは蛍
光標識ラテックス粒子に抗原に対する抗体を感作吸着さ
せた標識粒子をマトリックス試験片上に保持する。被検
試料と標識粒子を反応させ、マトリックス内の毛管流に
より移動させ、検出区域に保持させておいた抗体により
反応複合体を捕獲し、その信号を検出する。一方内部コ
ントロールは被検試料中の共存する物質の影響を実質的
に受けない反応対の物質として、例えばアビジンを吸着
させた金コロイドや着色もしくは蛍光標識ラテックス粒
子を試験片上に保持しておき、被検試料の添加によりマ
トリックス内を移動させる。内部コントロール域におい
て予め、ビオチンを保持させておくことにより移動して
きたアビジン粒子がアビジン−ビオチンの結合反応によ
り捕獲される。この信号を検出することにより、内部コ
ントロール信号が得られる。そして公知の方法において
両方の信号の比率を求め、既知濃度の試料を同様に操作
して得られる検量線データーと比較して被検物質を定量
する。
[0005] For example, when a test substance (antigen) is quantified by immunochromatographic measurement, labeled particles obtained by sensitizing and adsorbing an antibody against an antigen to colloidal gold or colored or fluorescently labeled latex particles are held on a matrix test piece. The test sample is reacted with the labeled particles, moved by capillary flow in the matrix, the reaction complex is captured by the antibody retained in the detection area, and the signal is detected. On the other hand, as an internal control, for example, a gold colloid or a colored or fluorescently labeled latex particle adsorbed with avidin is held on a test piece as a substance of a reaction pair substantially unaffected by a coexisting substance in a test sample, The sample is moved in the matrix by the addition of the test sample. Avidin particles that have been moved by holding biotin in advance in the internal control area are captured by the avidin-biotin binding reaction. By detecting this signal, an internal control signal is obtained. Then, the ratio of both signals is obtained by a known method, and the analyte is quantified by comparing with a calibration curve data obtained by similarly operating a sample of a known concentration.

【0006】内部コントロールの信号を生じさせ被検試
料中の共存物質の影響を実質的に受けない反応対の組合
わせは、上記のアビジン−ビオチンの他、ビオチン−ス
トレプトアビジン、さらにビオチン類縁体とアビジン若
しくはストレプトアビジンの組み合わせから選択され
る。さらに公知の方法では動物のIgGとそれに対する
抗体の組み合わせが示されているが、この場合には、動
物IgGに対する抗体がヒト血清中に存在することによ
り測定に影響を及ぼすことは前述の通りであるが、本発
明の方法では、人工的な化合物(ハプテン)を感作吸着
させた粒子とその化合物に対する抗体の組合わせも適当
である。例えば2,4−ジニトロフェノール(DNP)
を粒子に吸着させておき、内部コントロール信号検出域
に抗DNP抗体を保持させておくことができる。その他
の例として、フルオレセイン、ローダミン等とそれらに
対する抗体も有用である。しかし、公知の抗体を内部コ
ントロール粒子吸着させる方法と同じ方法である抗DN
P抗体を吸着させた粒子で、内部コントロール検出域に
DNPを保持させておく方法は、被検試料中に共存する
抗動物抗体やリウマチ因子の影響を受けるため適当では
ない。どのリガンド対を選択するかは、被検試料中に共
存する物質を考慮して選択すればよい。
[0006] The combination of a reaction pair that generates an internal control signal and is substantially unaffected by the coexisting substance in the test sample is a combination of avidin-biotin, biotin-streptavidin, and a biotin analog. It is selected from a combination of avidin or streptavidin. Further, in a known method, a combination of animal IgG and an antibody thereto is shown. In this case, it is as described above that the presence of the antibody against animal IgG in human serum affects the measurement. However, in the method of the present invention, a combination of an artificial compound (hapten) sensitized and adsorbed particles and an antibody against the compound is also suitable. For example, 2,4-dinitrophenol (DNP)
Can be adsorbed on the particles, and the anti-DNP antibody can be retained in the internal control signal detection area. As other examples, fluorescein, rhodamine and the like and antibodies thereto are also useful. However, anti-DN, which is the same method as that for adsorbing a known antibody to internal control particles, is used.
The method in which DNP is retained in the internal control detection region by the particles to which the P antibody is adsorbed is not suitable because it is affected by anti-animal antibodies and rheumatoid factors coexisting in the test sample. Which ligand pair should be selected may be selected in consideration of a substance coexisting in the test sample.

【0007】血液や血清等を被検試料とする場合には、
アビジンもしくはストレプトアビジンとビオチンの組合
わせやヒト血清中には存在しない酵素と基質、例えばマ
ンナーゼとマンナンの組合わせ等を選択することが有利
である。一方、被検試料が土壌中の環境ホルモン等を測
定するような場合には、ハプトグロビンとヘモグロビン
の組合わせ等も有利である。
When blood or serum is used as a test sample,
It is advantageous to select a combination of avidin or streptavidin and biotin or an enzyme and substrate that are not present in human serum, such as a combination of mannase and mannan. On the other hand, when the test sample measures environmental hormones or the like in soil, a combination of haptoglobin and hemoglobin is also advantageous.

【0008】従って、本発明の特徴の一つは、被検試料
の性質に対応して最適な内部コントロールを選択できる
ことである。
Therefore, one of the features of the present invention is that an optimum internal control can be selected according to the properties of a test sample.

【0009】本発明の具体的な実施態様の例を図1に示
す。部材1はニトロセルロースメンブラン、アセチルセ
ルロースメンブラン、セルロース濾紙、ガラス濾紙及び
ポリエチレン焼結体等のマトリックス試験片であり、部
位2はその試験片上に設置された試料添加部位である。
この試料添加部位には血球等の固形分を取り除くことが
できる分離フィルターや分離パッド、更に不織布ガーゼ
等による固形分除去用部材を設置することもできる。部
位3は標識粒子の保持部位であり、抗原を測定する場合
には、金コロイドや着色もしくは蛍光標識ラテックス粒
子に抗原に対する抗体を感作吸着させた標識粒子が保持
される。標識粒子は乾燥状態で保持されるのが一般的で
ある。この部位には内部コントロール用の粒子も保持さ
れる。内部コントロール用粒子は上記の被検物質用粒子
とは異なる信号を与える粒子が適当である。例えば、金
コロイドに対して、波長の異なる金属コロイドであると
か、着色粒子では吸収波長の異なる色素を着色した粒
子、更に蛍光色素では蛍光波長の異なる2種類の粒子を
用いる。内部コントロール用粒子の粒子径は、被検物質
用粒子の粒子径と同程度のものが適当である。粒子径の
差が大きいと被検試料の粘度等の影響により被検物質用
粒子と内部コントロール用粒子の毛管流による移動度が
異なり正確な分析ができなくなる恐れがある。内部コン
トロール粒子に吸着させる物質は前述のリガンド対の中
から、分析に適した組合わせを選択できる。アビジン−
ビオチンを選択する場合には、アビジンかビオチンのど
ちらか一方を粒子に吸着させ使用する。部位4は検出域
であり、抗原測定の場合には、一般に被検物質に対する
抗体が保持されている。被検試料中に被検物質が存在し
ていると被検物質と標識粒子が複合体を形成して、毛管
流により移動して部位4で捕獲される。捕獲された標識
粒子の信号を検出する。部位5は部位4に近接して設置
されており、内部コントロール域である。毛管流により
移動してきた内部コントロール粒子がこの部位でリガン
ド対の一方に捕獲される。例えば、アビジン吸着粒子を
内部コントロール粒子として用いた場合にはビオチンが
この部位に保持されており、ビオチン−アビジンの結合
により粒子が捕獲される。捕獲された粒子の信号を検出
する。被検物質により検出された信号と内部コントロー
ルにより検出された信号の比率を求め、予め既知濃度の
物質を含む試料を操作して得られた検量線と比較して、
被検物質を定量する。検出する信号は、色素の吸収、反
射、蛍光等が適用できる。
FIG. 1 shows an example of a specific embodiment of the present invention. The member 1 is a matrix test piece such as a nitrocellulose membrane, an acetylcellulose membrane, a cellulose filter paper, a glass filter paper, and a polyethylene sintered body, and the portion 2 is a sample addition portion provided on the test piece.
A separation filter or separation pad capable of removing solids such as blood cells, and a member for removing solids using a nonwoven fabric gauze or the like can be provided at the sample addition site. The site 3 is a site for holding labeled particles. When measuring an antigen, labeled particles obtained by sensitizing and adsorbing an antibody against the antigen to colloidal gold or colored or fluorescently labeled latex particles are held. Generally, the labeled particles are kept dry. This site also holds particles for internal control. As the particles for internal control, particles giving a signal different from the particles for the test substance are appropriate. For example, in contrast to gold colloid, metal colloids having different wavelengths are used, colored particles are colored with dyes having different absorption wavelengths, and fluorescent dyes are two types of particles having different fluorescence wavelengths. It is appropriate that the particle size of the internal control particles is substantially the same as the particle size of the test substance particles. If the difference between the particle diameters is large, the mobility of the particles for the test substance and the particles for the internal control due to the capillary flow may be different due to the influence of the viscosity of the test sample and the like, and accurate analysis may not be performed. As the substance to be adsorbed to the internal control particles, a combination suitable for analysis can be selected from the above-mentioned ligand pairs. Avidin-
When biotin is selected, either avidin or biotin is adsorbed on particles and used. Site 4 is a detection area, and in the case of antigen measurement, generally, an antibody against the test substance is retained. If a test substance is present in the test sample, the test substance and the labeled particles form a complex, move by capillary flow, and are captured at the site 4. The signal of the captured labeled particles is detected. Site 5 is located close to site 4 and is an internal control area. Internal control particles that have migrated by capillary flow are captured at one of the ligand pairs at this site. For example, when avidin-adsorbed particles are used as internal control particles, biotin is retained at this site, and the particles are captured by the biotin-avidin bond. Detect the signal of the captured particles. Determine the ratio of the signal detected by the test substance and the signal detected by the internal control, compared with a calibration curve obtained by previously operating a sample containing a substance of known concentration,
The test substance is quantified. As a signal to be detected, dye absorption, reflection, fluorescence and the like can be applied.

【0010】[0010]

【実施例】以下に実施例を挙げて本発明を更に説明する
が、本発明は実施例に限定されるものではない。
EXAMPLES The present invention will be further described below with reference to examples, but the present invention is not limited to the examples.

【0011】[0011]

【実施例1】(1)抗HBsモノクロナール抗体標識ラ
テックスの調製 抗HBsモノクロナール抗体(クローンHB0011)
を1mg/mLとなるように20mMリン酸緩衝液(p
H7.0)に希釈した。その希釈液10mL中に粒子径
0.25μmの青色ラテックス粒子の懸濁液(10%固
形分)1mLを加え混和後、室温で2時間放置した。1
5,000×g20分間遠心分離してラテックス粒子を
集め、10mg/mLの牛血清アルブミンを含む20m
Mリン酸緩衝液(BSA−リン酸緩衝液)10mLで3
回洗浄した。最終10mLのBSA−リン酸緩衝液に懸
濁した。
Example 1 (1) Preparation of anti-HBs monoclonal antibody-labeled latex Anti-HBs monoclonal antibody (clone HB0011)
Was adjusted to 1 mg / mL in a 20 mM phosphate buffer (p
H7.0). 1 mL of a suspension of blue latex particles having a particle size of 0.25 μm (10% solid content) was added to 10 mL of the diluted solution, mixed, and allowed to stand at room temperature for 2 hours. 1
The latex particles were collected by centrifugation at 5,000 × g for 20 minutes, and 20 μm containing 10 mg / mL bovine serum albumin.
M phosphate buffer (BSA-phosphate buffer)
Washed twice. Suspended in a final 10 mL of BSA-phosphate buffer.

【0012】(2)ビオチン標識ラテックスの調製 sulfo−NHS−LC−ビオチン(Sigma社
製)を0.1mg/mLとなるように20mMリン酸緩
衝液(pH7.0)に溶解し、その10mL中に粒子径
0.28μmの赤色ラテックス粒子の懸濁液(10固形
分)1mLを加え攪拌後、室温で2時間放置した。その
後15,000×g20分間遠心分離してラテックス粒
子を集め、10mg/mLの牛血清アルブミンを含む2
0mMリン酸緩衝液(BSA−リン酸緩衝液)10mL
で3回洗浄した。最終10mLのBSA−リン酸緩衝液
に懸濁した。
(2) Preparation of biotin-labeled latex Sulfo-NHS-LC-biotin (manufactured by Sigma) was dissolved in a 20 mM phosphate buffer (pH 7.0) to a concentration of 0.1 mg / mL, and the solution was dissolved in 10 mL of the solution. 1 mL of a suspension of red latex particles having a particle size of 0.28 μm (10 solids) was added to the mixture, and the mixture was stirred and left at room temperature for 2 hours. Thereafter, the mixture was centrifuged at 15,000 × g for 20 minutes to collect latex particles, and 2 mg of 10 mg / mL bovine serum albumin was added.
0 mM phosphate buffer (BSA-phosphate buffer) 10 mL
And washed three times. Suspended in a final 10 mL of BSA-phosphate buffer.

【0013】(3)上記の各ラテックス懸濁液を1:1
に混和した懸濁液中に、0.5%ポリビニールアルコー
ルを加え、不織布パッド(1cm×10cm、厚み2m
m)をその溶液中に浸漬して凍結乾燥した。そのパッド
を0.8cmの長さに切断して1テストの試験に用い
た。
(3) Each of the above latex suspensions is 1: 1
A 0.5% polyvinyl alcohol was added to the suspension mixed with the above, and a non-woven fabric pad (1 cm × 10 cm, thickness 2 m) was added.
m) was immersed in the solution and freeze-dried. The pad was cut to a length of 0.8 cm and used for one test.

【0014】(4)ニトロセルロース膜(1cm×10
cm)を試験片として用い、図1に示した様な加工を施
した。図中の部位4には抗HBsモノクロナール抗体
(クローンHB0022)を100μg/mLの10μ
Lを塗布し検出部位を設けた。図中の部位5にはアビジ
ンを100μg/mLの10μLを塗布しコントロール
部位を設けた。それぞれを塗布し乾燥後、ニトロセルロ
ース膜全体をBSA−リン酸緩衝液でブロッキングして
乾燥させた。このようにして調製した試験片の部位3に
上記(3)で作成した試験片をのせ、試料添加部位2と
毛管でつながるように不織布ガーゼで連絡した。
(4) Nitrocellulose membrane (1 cm × 10
cm) was used as a test piece and processed as shown in FIG. At site 4 in the figure, anti-HBs monoclonal antibody (clone HB0022) was added at 100 μg / mL for 10 μL.
L was applied to provide a detection site. At the site 5 in the figure, 10 μL of 100 μg / mL of avidin was applied to provide a control site. After coating and drying each, the entire nitrocellulose membrane was blocked with a BSA-phosphate buffer and dried. The test piece prepared in the above (3) was placed on the site 3 of the test piece prepared in this manner, and the test piece was connected to the sample addition site 2 with a nonwoven fabric gauze so as to be connected by a capillary.

【0015】(5)HBs抗原の測定 既知濃度のHBs抗原溶液(0、10、20、50、1
00ng/mL)をそれぞれ3滴(約120μL)試料
添加部に滴下し、8分後に薄層クロマト用デンシトメー
ター(島津製作所製)で波長410nmと530nmで
反射率を求めた。その結果を表1に示す。
(5) Measurement of HBs antigen A known concentration of HBs antigen solution (0, 10, 20, 50, 1)
(00 ng / mL) was added dropwise to the sample addition section, and after 8 minutes, the reflectance was determined at 410 nm and 530 nm using a densitometer for thin layer chromatography (manufactured by Shimadzu Corporation). Table 1 shows the results.

【0016】[0016]

【表1】 [Table 1]

【0017】上記の結果、HBs抗原濃度に依存した比
が得られ、HBs抗原の定量が可能であることが明らか
となった。
As a result, a ratio depending on the HBs antigen concentration was obtained, and it became clear that the HBs antigen could be quantified.

【0018】[0018]

【発明の効果】内部コントロールと被検試料の検出部の
信号比率により、被検試料を定量する際、共存物質の影
響を回避した特異性の高いアッセイ系を提供するもので
ある。
The present invention provides a highly specific assay system which avoids the influence of coexisting substances when quantifying a test sample by the signal ratio between the internal control and the detection section of the test sample.

【0019】[0019]

【図面の簡単な説明】[Brief description of the drawings]

【図1】 イムノクロマト法の図式例である。FIG. 1 is a schematic example of an immunochromatography method.

【符号の説明】[Explanation of symbols]

1・・・イムノクロマト支持体 2・・・試料添加部位 3・・・標識ラテックス部位 4・・・検出部位 5・・・コントロール部位 DESCRIPTION OF SYMBOLS 1 ... Immunochromatography support 2 ... Sample addition site 3 ... Labeled latex site 4 ... Detection site 5 ... Control site

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 流体試料中の被検物質の濃度を定量する
方法であって、 a)流体試料が毛管現象により移動できるマトリックス
を含む試験片であり、被検物質の濃度に対応した検出可
能な標識物質からの信号を検出する工程、 b)被検物質の濃度に依存することなしに検出可能な標
識物質からの信号(内部コントロール信号)を検出する
工程、 c)工程a)の信号と工程b)の信号の比率を決定する
工程、 d)工程c)で決定した信号の比率を既知の濃度の被検
物質を含有する流体試料について同様な方法で計測した
信号どうしの比率の計測と比較することにより、流体試
料中の被検物質の濃度を測定する工程を含むことからな
る流体試料中の被検物質の濃度を定量する方法におい
て、内部コントロール信号を生じさせ検出する工程に被
検試料中に共存する物質の影響を実質的に受けないリガ
ンド対の組合わせを用いることを特徴とする方法。
1. A method for quantifying the concentration of a test substance in a fluid sample, the method comprising: a) a test piece containing a matrix in which the fluid sample can move by capillary action, which can be detected according to the concentration of the test substance. B) detecting a signal (internal control signal) from the labeling substance which can be detected without depending on the concentration of the test substance; c) detecting the signal from the step a); Determining the ratio of the signals in step b), d) measuring the ratio of the signals determined in a similar manner for the fluid sample containing the analyte at a known concentration, and measuring the ratio of the signals determined in step c). The method for quantifying the concentration of a test substance in a fluid sample comprising the step of measuring the concentration of the test substance in the fluid sample by comparing Wherein the use of a combination of receiving no ligand to substantially the effects of the coexisting materials in the postal.
【請求項2】 内部コントロール信号を生じさせ検出す
る工程に被検試料中に共存する物質の影響を実質的に受
けないリガンド対の組合わせが少なくともビオチン若し
くはビオチン類縁体とアビジン若しくはストレプトアビ
ジンの組み合わせ又は、ハプテンと抗体の組合わせから
選ばれる請求項1記載の方法。
2. A combination of a ligand pair which is substantially unaffected by a substance coexisting in a test sample in a step of generating and detecting an internal control signal is at least a combination of biotin or a biotin analog and avidin or streptavidin. Alternatively, the method according to claim 1, which is selected from a combination of a hapten and an antibody.
【請求項3】 流体試料中の被検物質の濃度を定量する
装置であって、 a)流体試料が毛管現象により移動できるマトリックス
を含む試験片であり、被検物質の濃度に対応した検出可
能な標識物質からの信号を検出する工程、 b)被検物質の濃度に依存することなしに検出可能な標
識物質からの信号(内部コントロール信号)を検出する
工程、 c)工程a)の信号と工程b)の信号の比率を決定する
工程、 d)工程c)で決定した信号の比率を既知の濃度の被検
物質を含有する流体試料について同様な方法で計測した
信号どうしの比率の計測と比較することにより、流体試
料中の被検物質の濃度を測定する工程を含むことからな
る流体試料中の被検物質の濃度を定量する装置におい
て、内部コントロール信号を生じさせ検出する工程に被
検試料中に共存する物質の影響を実質的に受けないリガ
ンド対の組合わせを用いることを特徴とする装置。
3. An apparatus for quantifying the concentration of a test substance in a fluid sample, comprising: a) a test strip containing a matrix in which the fluid sample can move by capillary action, which can be detected in accordance with the concentration of the test substance. B) detecting a signal (internal control signal) from the labeling substance which can be detected without depending on the concentration of the test substance; c) detecting the signal from the step a); Determining the ratio of the signals in step b), d) measuring the ratio of the signals determined in a similar manner for the fluid sample containing the analyte at a known concentration, and measuring the ratio of the signals determined in step c). In an apparatus for quantifying the concentration of a test substance in a fluid sample comprising a step of measuring the concentration of the test substance in a fluid sample by comparing And wherein the use of combinations of ligand pair which does not substantially affected by the coexisting materials in the postal.
【請求項4】 内部コントロール信号を生じさせ検出す
る工程に被検試料中に共存する物質の影響を実質的に受
けないリガンド対の組合わせがビオチン若しくはビオチ
ン類縁体とアビジン若しくはストレプトアビジンの組み
合わせ又は、ハプテンと抗体の組合わせから選ばれる請
求項3記載の装置。
4. A combination of a ligand pair which is substantially unaffected by a substance coexisting in a test sample in a step of generating and detecting an internal control signal is a combination of biotin or a biotin analog and avidin or streptavidin, or 4. The device of claim 3, wherein the device is selected from a combination of a hapten and an antibody.
JP11234484A 1999-07-15 1999-07-15 Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece Pending JP2001033454A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11234484A JP2001033454A (en) 1999-07-15 1999-07-15 Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11234484A JP2001033454A (en) 1999-07-15 1999-07-15 Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece

Publications (1)

Publication Number Publication Date
JP2001033454A true JP2001033454A (en) 2001-02-09

Family

ID=16971756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11234484A Pending JP2001033454A (en) 1999-07-15 1999-07-15 Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece

Country Status (1)

Country Link
JP (1) JP2001033454A (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002071069A1 (en) * 2001-03-07 2002-09-12 Asahi Food & Healthcare Ltd. Method of analyzing specimen with the use of specific bond
JP2006208386A (en) * 2005-01-26 2006-08-10 Agilent Technol Inc Assay test strip with two or more markers, and reading method therefor
WO2006083367A2 (en) * 2004-11-23 2006-08-10 Response Biomedical Corporation Immunoassay employing two-step internal calibration reaction
JP2007232384A (en) * 2006-02-27 2007-09-13 Sysmex Corp Testing apparatus for chromatography, and its manufacturing method
WO2009028202A1 (en) * 2007-08-31 2009-03-05 Wakunaga Pharmaceutical Co., Ltd. Immunochromato device
JP2010014631A (en) * 2008-07-04 2010-01-21 Furukawa Electric Co Ltd:The Immunochromatographic conjugate pad containing fluorescent particle and colored particle as marker particle, and immunochromatographic test strip and inspection method using the same
JP2012510623A (en) * 2008-12-03 2012-05-10 エフ.ホフマン−ラ ロシュ アーゲー Test element with combined control and calibration zone
JP2013053869A (en) * 2011-09-01 2013-03-21 Furukawa Electric Co Ltd:The Immunochromatographic test kit, detection method using the same, and marker reagent to be used for the same
JP2013205335A (en) * 2012-03-29 2013-10-07 Mitsubishi Chemical Medience Corp Immunochromatographic test tool using avidin-biotin linkage labeling reagent, and use thereof
WO2014084260A1 (en) * 2012-11-28 2014-06-05 古河電気工業株式会社 Immunochromatography, and detector and reagent for use therein
JP2015230280A (en) * 2014-06-06 2015-12-21 凸版印刷株式会社 Detection method of analysis object and test strip for lateral flow
JP2016057280A (en) * 2014-09-10 2016-04-21 古河電気工業株式会社 Method and apparatus for detection or quantitative determination of biomolecule by competition method
JP2017067542A (en) * 2015-09-29 2017-04-06 株式会社 ベセル Inspection method and specimen device in immunochromatography
US9989527B2 (en) 2004-04-01 2018-06-05 Alverix, Inc. Lateral flow assay systems and methods
US10041941B2 (en) 2005-04-22 2018-08-07 Alverix, Inc. Assay test strips with multiple labels and reading same

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002267670A (en) * 2001-03-07 2002-09-18 Asahi Beer Yakuhin Kk Method of analyzing specimen by using specific bond
WO2002071069A1 (en) * 2001-03-07 2002-09-12 Asahi Food & Healthcare Ltd. Method of analyzing specimen with the use of specific bond
US9989527B2 (en) 2004-04-01 2018-06-05 Alverix, Inc. Lateral flow assay systems and methods
WO2006083367A3 (en) * 2004-11-23 2006-10-05 Response Biomedical Corp Immunoassay employing two-step internal calibration reaction
WO2006083367A2 (en) * 2004-11-23 2006-08-10 Response Biomedical Corporation Immunoassay employing two-step internal calibration reaction
US7659086B2 (en) 2004-11-23 2010-02-09 Response Biomedical Corporation Immunoassay employing two-step internal calibration reaction
US8192943B2 (en) 2004-11-23 2012-06-05 Response Biomedical Corporation Immunoassay employing two-step internal calibration reaction
JP2006208386A (en) * 2005-01-26 2006-08-10 Agilent Technol Inc Assay test strip with two or more markers, and reading method therefor
US11782058B2 (en) 2005-04-22 2023-10-10 Alverix, Inc. Diagnostic test system using measurement obtained from reference feature to modify operational parameter of reader
US10041941B2 (en) 2005-04-22 2018-08-07 Alverix, Inc. Assay test strips with multiple labels and reading same
US10191043B2 (en) 2005-04-22 2019-01-29 Alverix, Inc. Methods and systems for calibrating illumination source of diagnostic test system
US10753931B2 (en) 2005-04-22 2020-08-25 Alverix, Inc. Assay test strips with multiple labels and reading same
JP2007232384A (en) * 2006-02-27 2007-09-13 Sysmex Corp Testing apparatus for chromatography, and its manufacturing method
WO2009028202A1 (en) * 2007-08-31 2009-03-05 Wakunaga Pharmaceutical Co., Ltd. Immunochromato device
JP2010014631A (en) * 2008-07-04 2010-01-21 Furukawa Electric Co Ltd:The Immunochromatographic conjugate pad containing fluorescent particle and colored particle as marker particle, and immunochromatographic test strip and inspection method using the same
US8569073B2 (en) 2008-12-03 2013-10-29 Roche Diagnostics Operations Inc. Test element having combined control and calibration zone
JP2015079002A (en) * 2008-12-03 2015-04-23 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Test element with combination zone of contrast and calibration
JP2012510623A (en) * 2008-12-03 2012-05-10 エフ.ホフマン−ラ ロシュ アーゲー Test element with combined control and calibration zone
JP2013053869A (en) * 2011-09-01 2013-03-21 Furukawa Electric Co Ltd:The Immunochromatographic test kit, detection method using the same, and marker reagent to be used for the same
JP2013205335A (en) * 2012-03-29 2013-10-07 Mitsubishi Chemical Medience Corp Immunochromatographic test tool using avidin-biotin linkage labeling reagent, and use thereof
US10036750B2 (en) 2012-11-28 2018-07-31 Furukawa Electric Co., Ltd. Immunochromatography, and detection device and reagent for the same
JP5579343B1 (en) * 2012-11-28 2014-08-27 古河電気工業株式会社 Immunochromatography, detection device and reagent used therefor
WO2014084260A1 (en) * 2012-11-28 2014-06-05 古河電気工業株式会社 Immunochromatography, and detector and reagent for use therein
JP2015230280A (en) * 2014-06-06 2015-12-21 凸版印刷株式会社 Detection method of analysis object and test strip for lateral flow
JP2016057280A (en) * 2014-09-10 2016-04-21 古河電気工業株式会社 Method and apparatus for detection or quantitative determination of biomolecule by competition method
JP2017067542A (en) * 2015-09-29 2017-04-06 株式会社 ベセル Inspection method and specimen device in immunochromatography

Similar Documents

Publication Publication Date Title
FI92883B (en) Test procedure and reagent kit for this
JP3758814B2 (en) Response signal amplification method in sandwich immunoassay
JP3358737B2 (en) Assays with improved dose response curves
AU2007319076B2 (en) Saturation assay
JP2005189246A (en) Immunochromatographic assay of controlled sensitivity
WO1998039657A1 (en) Quantitative lateral flow assays and devices
JPH01123149A (en) Metal sol trapping immunoassay, kit used therefor and metal-containing composite material to be trapped
JPH08240591A (en) Method for determining quantity of material under inspectionon test piece for immunity chromatography
JP4274944B2 (en) Particle-based ligand assay with extended dynamic range
JP2001033454A (en) Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece
EP0564494B1 (en) Test method and reagent kit therefor
EP0248892A1 (en) Particle-bound binding component immunoassay
JP2005510706A5 (en)
JPWO2003029822A1 (en) Specific binding analyzer and specific binding analysis method
EP0882224A1 (en) Non-captive substrate liquid phase immunoassay
US7067264B2 (en) Test device for detecting human blood and method of use
JP2005077301A (en) Immunological detection carrier and measuring method
JP4212189B2 (en) Dry analysis method and dry analysis element
JPH11133023A (en) Compound for reducing influence of urea on chromatographic immunoassay using urine sample
EP0603958A1 (en) Improvement of the dynamic range in specific binding assays
JP2009192222A (en) Immunoassay method
JP4437211B2 (en) Measuring method using immunochromatography and sample analysis tool used therefor
JP2001228151A (en) Immunological chromatographic device
CN116413445A (en) Detection card, kit and detection method for detecting total thyroxine content
JP2001033453A (en) Measuring method for ligand

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20050928

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20051101